# Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors

> **NCT04056910** · PHASE2 · COMPLETED · sponsor: **Jason J. Luke, MD** · enrollment: 15 (actual)

## Conditions studied

- Advanced Solid Tumor
- IDH1 Mutation
- Glioma

## Interventions

- **DRUG:** ivosidenib and nivolumab

## Key facts

- **NCT ID:** NCT04056910
- **Lead sponsor:** Jason J. Luke, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-20
- **Primary completion:** 2023-11-13
- **Final completion:** 2023-11-13
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2025-02-27

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04056910

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04056910, "Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04056910. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*